| |
|
|
|
|
|
|
|||
|
Prepublished online as a Blood First Edition Paper on October 31, 2002; DOI 10.1182/blood-2002-06-1862.
HEMATOPOIESIS
From the Clinical Research Division, Fred Hutchinson
Cancer Research Center, Seattle, WA; and the Department of Pediatrics,
University of Washington, Seattle.
We investigated whether combined signaling induced by engineered
Notch ligands and hematopoietic growth factors influences hematopoietic
stem-cell differentiation. We show that incubation of murine marrow
precursors with Delta1ext-IgG, a Notch ligand
consisting of the Delta1 extracellular domain fused to the Fc
portion of human immunoglobulin G1 (IgG1), and growth factors
stem cell factor (SCF), interleukin 6 (IL-6), IL-11, and Flt3-l
inhibited myeloid differentiation and promoted a several-log increase
in the number of precursors capable of short-term lymphoid and myeloid
repopulation. Addition of IL7 promoted early T-cell development,
whereas addition of granulocyte-macrophage colony-stimulating factor
(GM-CSF) led to terminal myeloid differentiation. These results
support a role for combinatorial effects by Notch and cytokine-induced signaling pathways in regulating hematopoietic cell
fate and suggest the usefulness of Notch ligand in increasing hematopoietic precursor numbers for clinical stem-cell transplantation.
(Blood. 2003;101:1784-1789) The hematopoietic stem cell (HSC) is thought to
self-renew while also producing progeny committed to multiple
hematopoietic lineages, thereby generating the numerous blood cell
types required during an individual's lifetime. Although hematopoietic
growth factors have been shown to support differentiation and survival of HSCs, factors that enhance HSC self-renewal have yet to be identified. Combined effects of growth factors and the Notch
pathway have been shown to regulate cell-fate decisions in studies of eye and neural development in invertebrates, and increasing evidence indicates they may perform a similar role in
vertebrates.1-3
The Notch pathway regulates cell-fate decisions in a wide
variety of cell types, often inhibiting particular differentiation programs and permitting either self-renewal or differentiation along
alternate pathways.4,5 Notch receptors and Notch ligands have been found on hematopoietic precursors or marrow stromal cells.2,6-13 Retrovirus-mediated expression of activated
Notch1 enhanced self-renewal and immortalized hematopoietic
precursor cells in the context of appropriate
cytokines,14,15 indicating Notch's potential capacity for
enhancing stem cell self-renewal in nonmutant cells. However, multiple
studies have reported only a modest increase in hematopoietic precursor
cell numbers following culture with Notch ligand presented on cell
surfaces or with engineered Notch ligands in
solution.12,16-21 Here, we show that an optimally presented engineered Notch ligand induces an extensive expansion of
hematopoietic precursor cell numbers in a similar manner to retroviral-mediated expression of activated Notch
constructs. We show that Notch signaling induced by
immobilized engineered Notch ligand Delta1ext-IgG,
consisting of the Delta1 extracellular domain fused to the Fc domain of
human immunoglobulin G1 (IgG1), induced a multiple-log increase
in the number of precursor cells capable of short-term lymphoid and
myeloid reconstitution and longer-term T-lymphoid reconstitution in nonobese diabetic/severe combined
immunodeficiency (NOD/SCID) recipients.
Protein purification
Hematopoietic cell culture and flow immunocytometry
Flow analysis Cultured cells were resuspended in PBS containing 2% FBS (PBS/FBS). All reagents for flow analysis were diluted in PBS/FBS. Cells were preincubated with antimouse CD16/CD32 (Fc RII block) for
10 minutes at 4°C and stained with phycoerythrin
(PE)-conjugated monoclonal antibodies: Sca-1 (anti-Ly-6A/E),
anti-c-kit (clone 2B9), anti-Thy1.2 (clone 53-2.1), anti-CD19 (clone
ID3), GR-1 (anti-Ly6-G, clone RB6-8C5), anti-CD25 (PE-IL-2 receptor,
chain, PC61-IgG1; biotin-7D4-IgM), anti-CD4 (clone RM4-5), anti-CD8
(clone 53-6.7), PE-conjugated isotype matched control antibodies
(Pharmingen, San Diego, CA), and F4/80 (antimacrophage, Caltag,
Burlingame, CA). For simultaneous staining of CD4 and CD8, cells were
incubated with biotinylated anti-CD8 and PE-conjugated anti-CD4 and
stained cells were detected with Avidin-Red-670 (Gibco-BRL, Grand
Island, NY). In all cases, stained cells were washed with PBS/FBS and resuspended in PBS/FBS containing 12.5 µg/mL propidium iodide to gate
for dead cells.
Competitive and noncompetitive repopulation assays Congenic C57BL/6.SJL-Ly5.1-Pep3b (Ly5.1) mice and NOD/SCID mice were bred at the Fred Hutchinson Cancer Research Center (Seattle, WA). All mice were housed in specific pathogen-free conditions and maintained on autoclaved chow ad libitum. Cultured Ly5.2 cells (1.0 to 10.0 × 106) were intravenously injected together with normal Ly5.1 bone marrow cells (1 × 105) in the tail vein of C57BL/6.SJL-Ly5.1-Pep3b recipients that had received a single dose of 10.0-Gy -irradiation from a linear accelerator at an
exposure rate of 20 cGy per minute on the day before or the day of
transplantation. Cultured Ly5.2 cells were injected intravenously into
NOD/SCID recipients that had received a sublethal single dose of 3.5-Gy
-irradiation. Peripheral blood in transplant recipients was obtained
from the retro-orbital sinus. Red blood cells were removed with
ammonium chloride lysis buffer and remaining nucleated cells were
washed in PBS/FBS, preincubated with Fc RII block for 10 minutes at
4°C, and stained with the respective PE-conjugated lineage-specific antibodies as described in "Flow analysis." To identify
Ly5.2+ donors, cells were stained with a biotinylated
monoclonal antibody specific for Ly5.2 (clone 104) and Ly5.1 (clone
A20; kind gifts from Dr G. Spangrude, University of Utah, Salt Lake
City) or biotinylated mouse IgG2a for 30 minutes at 4°C and stained
cells were detected with Avidin-Red-670. In all cases, stained cells
were washed with PBS/FBS, resuspended in PBS/FBS containing 12.5 µg/mL propidium iodide, and analyzed by BD FACSCalibur (Becton
Dickinson, Mountain View, CA).
Notch signaling inhibits myeloid differentiation Recently we showed that in S20 cells and C2 myoblasts, optimal Notch signaling required immobilization of engineered Notch ligands, such as on a plastic tissue-culture plate (Figure 1A-B).22 To test whether this was also true with hematopoietic precursors, we incubated isolated Lin Sca-1+c-kit+ cells from
C57/Bl6Ly5.2 mice with plastic-bound immobilized
Delta1ext-IgG (I-Deltaext-IgG),
immobilized ControlIgG (I-ControlIgG), or
nonimmobilized Deltaext-IgG
(NI-Delta1ext-IgG) as well as growth factors
SCF, IL-6, IL-11, and Flt-3l (4GF), which support self-renewal of HSC
constitutively expressing activated Notch1.14
Delta1ext-IgG consisted of the extracellular domain of the
Notch ligand, Delta1, fused to the Fc domain of human IgG1 (Figure 1A).
Control molecules consisted of a signal peptide fused to the Fc
domain of human IgG1 (Figure 1A; ControlIgG) or purified
human IgG1.22
We found that immobilized, but not soluble, Notch ligand together with
4GF inhibited myeloid differentiation, while allowing self-renewal of
precursor cells. At 14 days, a similar increase in cell number was
observed in all cultures, whereas after 21 to 28 days, the increase
continued only in cultures with I-Delta1ext-IgG (Figure
1B). In a typical experiment, 1 × 103 sorted
Lin At 28 days, most cells incubated with I-Deltaext-IgG
continued to resemble blast cells (data not shown), and
66.7% ± 17.1% (mean ± SEM) expressed Sca-1 and c-kit in 3 separate experiments (Figure 2 shows a
representative experiment). In addition, 17.8% ± 7.1% expressed
the low-affinity IL-2 receptor CD25, and 16.7% ± 9.9% expressed
GR-1. None of the cells expressed the mature T-cell antigens CD4 or CD8
or the B-cell antigen CD19. In 4 of 6 experiments, cell numbers in
cultures incubated with I-Delta1ext-IgG steadily increased
for at least 42 days, when the experiments were voluntarily ended
(Figure 1B).
Notch signaling promotes early T-cell differentiation Detection of the CD25 antigen in a subpopulation of cells cultured with I-Delta1ext-IgG suggested that a portion of cells had undergone early T-cell differentiation. After adding IL-7, a cytokine known to support lymphoid cells, we found further indications of early T-cell differentiation. Cell number steadily increased in cultures of Lin Sca-1+c-kit+ cells containing
4GF, IL-7, and I-Delta1ext-IgG (Figure 2A), and most cells
resembled blasts expressing both Sca-1 and c-kit, similar to cultures
without IL-7 (Figure 2B; 78.7% ± 9.5% [mean ± SEM of 3 separate experiments]). However, after 21 to 28 days, most cells
(72.8% ± 10.4%) expressed CD25, many coexpressed CD25 and Thy1
(Figure 2B), and cytoplasmic CD3 mRNA was detected by reverse
transcriptase-polymerase chain reaction (RT-PCR; data not
shown), all indicative of early T-cell differentiation. Few cells
(0.9% ± 0.1%) expressed GR-1 (Figure 2B). In contrast, cultures
containing 4GF, IL-7, and I-ControlIgG were mainly
nonproliferating myeloid cells by 21 to 28 days (data not shown).
Cultures with 4GF plus IL-7 and I-Deltaext-IgG contained
more viable cells and cell numbers increased at a faster rate than in
similar cultures without IL-7 (Figure 2A), presumably reflecting
survival of an IL-7-dependent lymphoid subpopulation. In each of 7 experiments, cells in cultures that included IL-7 along with 4GF
continued to increase in number after 28 days for up to 42 days, when
the experiments were voluntarily ended.
To show that Notch signaling was required for continued generation of
Sca-1+c-kit+ precursors,
Lin
To determine the developmental potential of undifferentiated precursors
that had been incubated for 28 days with 4GF and
I-Delta1ext-IgG, granulocyte-macrophage colony-stimulating
factor (GM-CSF) or IL-7, which support myeloid and lymphoid
differentiation, respectively, were added along with 4GF and
I-Delta1ext-IgG. Cell numbers steadily increased for up to
about 12 days; however, after 15 days, cell numbers stopped increasing
in cultures with GM-CSF, but continued to increase steadily in cultures
with IL-7 (Figure 4A). The proportion of
cells expressing CD25 or both CD25 and Thy-1 was also increased in
cultures with IL-7, indicating early T-cell differentiation like that
seen when IL-7 was present from the initiation of the culture (Figure
2B), and consistent with previous demonstrations that activated Notch-1
permits or promotes T-cell differentiation.23 In
contrast, most cells in cultures containing GM-CSF underwent myeloid
differentiation, as indicated by morphology (data not shown) and
expression of GR-1 (Figure 4B). Thus, cultures of
Lin
Notch signaling increases short-term repopulating cell numbers To assess whether Notch signaling affects in vivo repopulating ability, Lin Sca-1+c-kit+ cells
were cultured for 28 days with 4GF, IL-7, and
I-Delta1ext-IgG in 3 separate experiments. In these
experiments, 1 × 103 cells initially placed in culture
generated at least 4 × 1013 cells. We injected 5 to
10 × 106 cultured cells (the progeny of 0.004 cells initially placed into culture) into each of 4 or 5 lethally
irradiated (1000 cGy) congenic mice
(C57BL/6.SJL-Ly5.1-Pep3b) along with 105
syngeneic Ly 5.1 bone marrow cells. After 3 weeks, peripheral blood
contained a mean of 28.6% ± 10.3% Ly5.2 donor cells (mean of 3 experiments; Figure 5A). This level of
reconstitution at 3 weeks was comparable to that detected in peripheral
blood from mice injected with 100 uncultured
Lin Sca-1+c-kit+ cells
(20.8% ± 8.6%; mean of 4 experiments). In mice receiving cells
cultured with I-Delta1ext-IgG, most donor cells (91%) were
myeloid, expressing lineage markers GR-1 and F4/80, but a portion of
cells (9%) expressed the T-cell marker CD4 or CD8 or the B-cell marker
CD19 (Figure 5B). At 5 to 6 weeks after injection, recipients of
cultured cells contained a reduced percentage of Ly5.2 donor cells in
their peripheral blood (4.5% ± 0.3%; mean of 3 experiments), and
donor cells were predominantly lymphoid rather than myeloid (Figure
5B). However, at 9 weeks, most donor cells detected (80%) were
lymphoid, of which nearly all (75%) were T lymphocytes. Similar or
decreased reconstitution was found for cells cultured without IL-7
added to 4GF and I-Delta1ext-IgG (data not shown). Thus,
Notch ligand in combination with appropriate cytokines induced at least
a 4- to 5-log increase in cells capable of short-term repopulation of
myeloid and lymphoid lineages.
To evaluate longer-term T-cell reconstitution, in 1 experiment
representative of 3 similar experiments,
Lin
These studies indicate that Notch signaling combined with
appropriate cytokines regulates cell-fate choices by multipotent hematopoietic precursors. Culture of
Lin Early T-cell differentiation was promoted in cultures containing I-Delta1ext-IgG that was further enhanced by IL-7. There was no evidence of B-cell differentiation in these cultures, in agreement with recent studies showing that constitutive Notch signaling or Notch signaling induced with the Notch ligand Delta1 inhibits B-cell differentiation presumably from a common lymphoid precursor.23,24 Longer-term T-cell reconstitution was seen in NOD/SCID recipients, but it is unknown whether it derived from longer-term reconstituting stem cells or from postthymic events with mature T cells. Although these studies do not reveal whether Notch signaling leads to early T-lymphoid differentiation by inhibiting a myeloid fate or by directing a lymphoid fate, no cytokine combination has been found to induce T-cell differentiation in vitro in the absence of fetal thymic organ culture, making it likely that Delta1 is promoting the observed lymphoid differentiation. Terminal myeloid differentiation did occur after the addition of GM-CSF
to 4GF with I-Delta1ext-IgG (Table
1), indicating that Notch signaling,
while able to inhibit myeloid differentiation signals induced by 4GF,
did not inhibit differentiation induced by GM-CSF. Alternatively,
GM-CSF signaling may inhibit Notch signaling by down-regulating Notch
expression or expression of essential molecules in the Notch pathway.
Thus, combinatorial signals from Notch and cytokine receptors determine whether multipotent hematopoietic precursors expand in numbers or
whether they assume an alternative lymphoid or myeloid fate (Table 1).
The results of this study demonstrate that the combination of Notch and cytokine-induced signaling pathways has the potential to regulate hematopoietic progenitor cell-fate decisions and indicate further that elucidating these signaling pathways in hematopoietic precursors may improve our understanding of and ability to affect stem cell self-renewal. The potential role of Notch in stem cell self-renewal is likely to involve suppression of multiple differentiation pathways by modulating expression of those proteins that can inhibit differentiation. For example, Notch signaling induces Id gene expression.25 Id proteins are dominant-negative inhibitors of E-proteins that are required for expression of proteins involved in differentiation, including B- and T-cell differentiation in hematopoiesis.26 Notch signaling has also been shown to prolong GATA-2 expression, a known inhibitor of myeloid differentiation.27 In addition, Notch signaling also could inhibit multiple differentiation programs by inducing HES-1 expression, which, in association with corepressor complexes that include other regulatory molecules, such as groucho, represses transcription of target regulatory genes that generally induce differentiation and/or commitment. HES-1 is thought to inhibit E2A expression, an inducer of gene targets such as EBF and PAX5 involved in B-cell commitment.28 HES-1 has also been shown to interact with AML1 to affect differentiation programs.29 Further clarification of interacting cytokine and Notch signaling pathways may elucidate the mechanisms of stem cell self-renewal, a goal that may be more readily achieved with the ability to grow substantial numbers of cells in the presence of Delta1.
We thank G. Radich, S. Collins, B. Clurman, A. Blau, E. Giniger, and K. Ohishi for criticism of the manuscript. We also thank David Flowers and Cynthia Nourigat for superb technical assistance.
Submitted June 21, 2002; accepted October 10, 2002.
Prepublished online as Blood First Edition Paper, October 31, 2002; DOI 10.1182/blood-2002-06-1862.
Supported by grants P50HL54881 and P30DK56465 from the National Institutes of Health. I.D.B. is also supported as an American Cancer Society-F.M. Kirby Clinical Research Professor.
The publication costs of this article were defrayed in part by page charge payment. Therefore, and solely to indicate this fact, this article is hereby marked "advertisement" in accordance with 18 U.S.C. section 1734.
Reprints: Irwin D. Bernstein, Clinical Research Division, Fred Hutchinson Cancer Research Center, 1100 Fairview Ave N, D2-373, Seattle, WA 98109; e-mail: ibernste{at}fhcrc.org.
1. Flores GV, Duan H, Yan H, et al. Combinatorial signaling in the specification of unique cell fates. Cell. 2000;103:75-85[CrossRef][Medline] [Order article via Infotrieve].
2.
Ohishi K, Varnum-Finney B, Flowers D, Anasetti C, Myerson D, Bernstein I.
Monocytes express high amounts of Notch and undergo cytokine specific apoptosis following interaction with the Notch ligand, Delta-1.
Blood.
2000;95:2847-2854
3.
Faux CH, Turnley AM, Epa R, Cappai R, Bartlett PF.
Interactions between fibroblast growth factors and Notch regulate neuronal differentiation.
J Neurosci.
2001;21:5587-5596
4.
Artavanis-Tsakonas S, Rand MD, Lake RJ.
Notch signaling: cell fate control and signal integration in development.
Science.
1999;284:770-776 5. Simpson P. Introduction: Notch signalling and choice of cell fates in development. Semin Cell Dev Biol. 1998;9:581-582[CrossRef][Medline] [Order article via Infotrieve]. 6. Ellisen LW, Bird J, West DC, et al. TAN-1, the human homolog of the Drosophila notch gene, is broken by chromosomal translocations in T lymphoblastic neoplasms. Cell. 1991;66:649-661[CrossRef][Medline] [Order article via Infotrieve]. 7. Del Amo FF, Smith DE, Swiatek PJ, et al. Expression pattern of Motch, a mouse homolog of Drosophila Notch, suggests an important role in early postimplantation mouse development. Development. 1992;115:737-744[Abstract]. 8. Weinmaster G, Roberts VJ, Lemke G. A homolog of Drosophila Notch expressed during mammalian development. Development. 1991;113:199-205[Abstract]. 9. Weinmaster G, Roberts VJ, Lemke G. Notch2: a second mammalian Notch gene. Development. 1992;116:931-941[Abstract]. 10. Li L, Milner LA, Deng Y, et al. The human homolog of rat Jagged1 expressed by marrow stroma inhibits differentiation of 32D cells through interaction with Notch1. Immunity. 1998;8:43-55[CrossRef][Medline] [Order article via Infotrieve].
11.
Coffman C, Harris W, Kintner C.
Xotch, the Xenopus homolog of Drosophila notch.
Science.
1990;249:1438-1441
12.
Varnum-Finney B, Purton LE, Yu M, et al.
The Notch ligand, Jagged-1, influences the development of primitive hematopoietic precursor cells.
Blood.
1998;91:4084-4091
13.
Tsai S, Fero J, Bartelmez S.
Mouse Jagged2 is differentially expressed in hematopoietic progenitors and endothelial cells and promotes the survival and proliferation of hematopoietic progenitors by direct cell-to-cell contact.
Blood.
2000;96:950-957 14. Varnum-Finney B, Xu L, Brashem-Stein C, et al. Pluripotent, cytokine-dependent, hematopoietic stem cells are immortalized by constitutive Notch1 signaling. Nat Med. 2000;6:1278-1281[CrossRef][Medline] [Order article via Infotrieve].
15.
Stier S, Cheng T, Dombkowski D, Carlesso N, Scadden DT.
Notch1 activation increases hematopoietic stem cell self-renewal in vivo and favors lymphoid over myeloid lineage outcome.
Blood.
2002;99:2369-2378
16.
Carlesso N, Aster JC, Sklar J, Scadden DT.
Notch1-induced delay of human hematopoietic progenitor cell differentiation is associated with altered cell cycle kinetics.
Blood.
1999;93:838-848
17.
Jones P, May G, Healy L, et al.
Stromal expression of Jagged 1 promotes colony formation by fetal hematopoietic progenitor cells.
Blood.
1998;92:1505-1511
18.
Han W, Ye Q, Moore M.
A soluble form of human Delta-like-1 inhibits differentiation of hematopoietic progenitor cells.
Blood.
2000;95:1616-1625 19. Walker L, Lynch M, Silverman S, et al. The Notch/Jagged pathway inhibits proliferation of human hematopoietic progenitors in vitro. Stem Cells. 1999;17:162-171[Medline] [Order article via Infotrieve].
20.
Karanu F, Murdoch B, Gallacher L, et al.
The Notch ligand Jagged-1 represents a novel growth factor of human hematopoietic stem cells.
J Exp Med.
2000;192:1365-1372
21.
Karanu F, Murdoch B, Miyabayashi T, et al.
Human homologues of Delta-1 and Delta-4 function as mitogenic regulators of primitive human hematopoietic cells.
Blood.
2001;97:1960-1967 22. Varnum-Finney B, Wu L, Yu M, et al. Immobilization of Notch ligand, Delta-1, is required for induction of Notch signaling. J Cell Sci. 2000;113:4313-4318[Abstract]. 23. Pui JC, Allman D, Xu L, et al. Notch1 expression in early lymphopoiesis influences B versus T lineage determination. Immunity. 1999;11:299-308[CrossRef][Medline] [Order article via Infotrieve].
24.
Jeleco AC, Neves H, Hooijberg E, et al.
Differential effects of Notch ligands Delta-1 and Jagged-1 in human lymphoid differentiation.
J Exp Med.
2001;194:991-1001 25. Reynaud-Deonauth S, Zhang H, Afouda A, et al. Notch signaling is involved in the regulation of Id3 gene transcription during Xenopus embryogenesis. Differentiation. 2002;69:198-208[CrossRef][Medline] [Order article via Infotrieve]. 26. Engel I, Murre C. The function of E- and ID proteins in lymphocyte development. Nat Rev Immunol. 2001;1:193-199[CrossRef][Medline] [Order article via Infotrieve].
27.
Kumano K, Chiba S, Shimizu K, et al.
Notch1 inhibits differentiation of hematopoietic cells by sustaining GATA-2 expression.
Blood.
2001;98:3283-3289 28. Kawamata S, Du C, Li K, Lavau C. Overexpression of the Notch target genes Hes in vivo induces lymphoid and myeloid alterations. Oncogene. 2002;21:3855-3863[CrossRef][Medline] [Order article via Infotrieve].
29.
McLarren KW, Lo R, Grbavec D, Thirunavukkarasu K, Karsenty G, Stifani S.
The mammalian basic helix loop helix protein HES-1 binds to and modulates the transactivating function of the runt-related factor Cbfa1.
J Biol Chem.
2000;275:530-538
© 2003 by The American Society of Hematology.
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
![]() |
H. Abdel-Azim, Y. Zhu, R. Hollis, X. Wang, S. Ge, Q.-L. Hao, G. Smbatyan, D. B. Kohn, M. Rosol, and G. M. Crooks Expansion of multipotent and lymphoid-committed human progenitors through intracellular dimerization of Mpl Blood, April 15, 2008; 111(8): 4064 - 4074. [Abstract] [Full Text] [PDF] |
||||
![]() |
B. Varnum-Finney, M. H. Dallas, K. Kato, and I. D. Bernstein Notch target Hes5 ensures appropriate Notch induced T- versus B-cell choices in the thymus Blood, March 1, 2008; 111(5): 2615 - 2620. [Abstract] [Full Text] [PDF] |
||||
![]() |
U. Blank, G. Karlsson, and S. Karlsson Signaling pathways governing stem-cell fate Blood, January 15, 2008; 111(2): 492 - 503. [Abstract] [Full Text] [PDF] |
||||
![]() |
H. Araki, K. Yoshinaga, P. Boccuni, Y. Zhao, R. Hoffman, and N. Mahmud Chromatin-modifying agents permit human hematopoietic stem cells to undergo multiple cell divisions while retaining their repopulating potential Blood, April 15, 2007; 109(8): 3570 - 3578. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. H. Dallas, B. Varnum-Finney, P. J. Martin, and I. D. Bernstein Enhanced T-cell reconstitution by hematopoietic progenitors expanded ex vivo using the Notch ligand Delta1 Blood, April 15, 2007; 109(8): 3579 - 3587. [Abstract] [Full Text] [PDF] |
||||
![]() |
P. Cheng, Y. Nefedova, C. A. Corzo, and D. I. Gabrilovich Regulation of dendritic-cell differentiation by bone marrow stroma via different Notch ligands Blood, January 15, 2007; 109(2): 507 - 515. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Garcia-Peydro, V. G. de Yebenes, and M. L. Toribio Notch1 and IL-7 Receptor Interplay Maintains Proliferation of Human Thymic Progenitors while Suppressing Non-T Cell Fates J. Immunol., September 15, 2006; 177(6): 3711 - 3720. [Abstract] [Full Text] [PDF] |
||||
![]() |
L. M. Calvi Hematopoietic-Osteoblastic Interactions in the Hematopoietic Stem Cell Niche IBMS BoneKEy, May 1, 2006; 3(5): 10 - 18. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. F. de Pooter, T. M. Schmitt, J. L. de la Pompa, Y. Fujiwara, S. H. Orkin, and J. C. Zuniga-Pflucker Notch Signaling Requires GATA-2 to Inhibit Myelopoiesis from Embryonic Stem Cells and Primary Hemopoietic Progenitors J. Immunol., May 1, 2006; 176(9): 5267 - 5275. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. Huang, K. P. Garrett, R. Pelayo, J. C. Zuniga-Pflucker, H. T. Petrie, and P. W. Kincade Propensity of Adult Lymphoid Progenitors to Progress to DN2/3 Stage Thymocytes with Notch Receptor Ligation J. Immunol., October 15, 2005; 175(8): 4858 - 4865. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. Delaney, B. Varnum-Finney, K. Aoyama, C. Brashem-Stein, and I. D. Bernstein Dose-dependent effects of the Notch ligand Delta1 on ex vivo differentiation and in vivo marrow repopulating ability of cord blood cells Blood, October 15, 2005; 106(8): 2693 - 2699. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. E. Burns, D. Traver, E. Mayhall, J. L. Shepard, and L. I. Zon Hematopoietic stem cell fate is established by the Notch-Runx pathway Genes & Dev., October 1, 2005; 19(19): 2331 - 2342. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. Maeda, Y. Baba, Y. Nagai, K. Miyazaki, A. Malykhin, K. Nakamura, P. W. Kincade, N. Sakaguchi, and K. M. Coggeshall IL-6 blocks a discrete early step in lymphopoiesis Blood, August 1, 2005; 106(3): 879 - 885. [Abstract] [Full Text] [PDF] |
||||
![]() |
L. M. Sarmento, H. Huang, A. Limon, W. Gordon, J. Fernandes, M. J. Tavares, L. Miele, A. A. Cardoso, M. Classon, and N. Carlesso Notch1 modulates timing of G1-S progression by inducing SKP2 transcription and p27Kip1 degradation J. Exp. Med., July 5, 2005; 202(1): 157 - 168. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. H. Dallas, B. Varnum-Finney, C. Delaney, K. Kato, and I. D. Bernstein Density of the Notch ligand Delta1 determines generation of B and T cell precursors from hematopoietic stem cells J. Exp. Med., May 2, 2005; 201(9): 1361 - 1366. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. J. C. Mancini, N. Mantei, A. Dumortier, U. Suter, H. R. MacDonald, and F. Radtke Jagged1-dependent Notch signaling is dispensable for hematopoietic stem cell self-renewal and differentiation Blood, March 15, 2005; 105(6): 2340 - 2342. [Abstract] [Full Text] [PDF] |
||||
![]() |
B. K. Hadland, S. S. Huppert, J. Kanungo, Y. Xue, R. Jiang, T. Gridley, R. A. Conlon, A. M. Cheng, R. Kopan, and G. D. Longmore A requirement for Notch1 distinguishes 2 phases of definitive hematopoiesis during development Blood, November 15, 2004; 104(10): 3097 - 3105. [Abstract] [Full Text] [PDF] |
||||
![]() |
V. Vas, L. Szilagyi, K. Paloczi, and F. Uher Soluble Jagged-1 is able to inhibit the function of its multivalent form to induce hematopoietic stem cell self-renewal in a surrogate in vitro assay J. Leukoc. Biol., April 1, 2004; 75(4): 714 - 720. [Abstract] [Full Text] [PDF] |
||||
![]() |
P. Cheng, Y. Nefedova, L. Miele, B. A. Osborne, and D. Gabrilovich Notch signaling is necessary but not sufficient for differentiation of dendritic cells Blood, December 1, 2003; 102(12): 3980 - 3988. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. Klarmann, M. Ortiz, M. Davies, and J. R. Keller Identification of in vitro growth conditions for c-Kit-negative hematopoietic stem cells Blood, November 1, 2003; 102(9): 3120 - 3128. [Abstract] [Full Text] [PDF] |
||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Copyright © 2003 by American Society of Hematology Online ISSN: 1528-0020 | |||||||||